References
- Oldham R K. Biologicals: new horizons in pharmaceutical development. J Biol Respir Modif 1983; 2: 199–206
- Oldham R K. Biologicals for cancer treatment: interferon. Hosp Pract 1985; 20: 72–91
- Oldham R K. Who pays for new drugs. Nature 1988; 332(28)795
- Oldham R K. Regulatory hierarchies. Mol Bioither 1988; 1(1)3–6
- Oldham R K. Cancer cures: by the people, for the people, at what cost. Mol Biother 1990; 2(1)2–3
- Oldham R K. Cancer research for whom. Bio/Technology 1991; 9(8)772
- Rosenberg S A, Aebersold P, Cornetta K. Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–578
- Rosenberg S A, Packard B S, Topalian S L. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676–1680
- Maleckar J R, Friddell C S, Sferruzza A. Activation and expansion of tumor derived activated cells for therapeutic use. J Natl Cancer Inst 1989; 1(21)1655–1660
- Oldham R K, Dillman R O, Yannelli J R. Continuous infusion interleukin-2 and tumor derived activated cells as treatment of advanced solid tumors: an NBSG trial. Mol Biother 1991; 3(2)68–73
- Dillman R O, Oldham R K, Barth N M. Continuous interleukin-2 and tumor derived activated cells as treatment of advanced melanoma. Cancer 1991, (in press)
- Oldham R K. Clinical research in cancer: a time for consensus. Pharm Exec July, 1989; 23–24
- Oldham R K. Cancer research: a public trust. BioPharmaceutics 1991; 4(3)8–9
- Oldham R K. The rights and wrongs of national health care. Pharm Exec 1991; 11(4)92–93
- Oldham R K. Is informed consent a function of who pays. Mol Biother 1991; 3(1)2–5
- Avent R A, Birch R, Oldham R K. Successful clinical trials in the private sector: the NBSG experience. Adv Cancer Control 1990; 339: 419–423
- Oldham R K. In cancer research, put the patient first. Wall Street J Aug 7, 1991